Financial Data and Key Metrics Changes - The company reported revenue of $1.057 billion for Q2 2023, a decline of 10% or 9% in constant currency, with price contributing 4% to the quarter's performance [51][56] - Adjusted EBITDA was $222 million, reflecting a decline of 27%, with an estimated headwind from the ERP blackout impacting results [56] - The company raised its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, now expecting revenue between $4.35 billion and $4.41 billion [85][73] Business Line Data and Key Metrics Changes - U.S. Pet Health returned to growth with a 1% increase year-over-year, driven by strong performance in the OTC retail market and new product launches [29][41] - International Pet Health declined 7% in constant currency, primarily due to demand pressure in the Spain retail market, but the European launch of Adtab exceeded expectations [41][67] - The International Farm Animal business grew 4% in constant currency, driven by strength in poultry and aqua, while the U.S. Farm Animal business declined 5% due to supply disruptions [42][53] Market Data and Key Metrics Changes - The U.S. Pet Health market saw a strong parasiticides season contributing to growth in both units and total sales, with Seresto and Advantage brands growing revenue in high-single digits [29][30] - The company noted a 36% increase in total touch points with veterinarians and clinics, contributing to stabilization in the U.S. vet market [30] - The company expects improvement in the International Pet Health business in the second half of 2023, leveraging innovation and a better economic environment in Europe [41] Company Strategy and Development Direction - The company is focused on increasing manufacturing capacity for its canine parvovirus monoclonal antibody by 10x, anticipating significant sales growth in 2024 [9][35] - The company is investing in its U.S. Pet Health business to maximize the potential of its portfolio, including new product launches and global market expansion [47][49] - The company aims to enhance its innovation pipeline, with several late-stage products expected to contribute significantly to revenue starting in 2024 [38][75] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to revenue growth in the second half of 2023, driven by new product ramps and improved supply for vaccines [86][89] - The company highlighted the importance of its late-stage pipeline and the expected differentiation of its products, which is critical for long-term success [75][92] - Management noted that the resolution of the EPA review for Seresto is a positive development, reaffirming the product's long-term growth potential [45][121] Other Important Information - The company completed its ERP integration, which is expected to provide synergies and improve operational efficiency [44][51] - The company ended the quarter with net debt of $5.75 billion and plans to retire $344 million of notes due in 2023 [59][60] - The company anticipates a year-end net leverage ratio between 5.5x and 5.8x, reflecting durable cash flows and a focus on debt paydown [60][84] Q&A Session Summary Question: Can you discuss the assumptions for the fast growth of parvo? - Management highlighted the strong start for the parvovirus product, with early efficacy reports showing quicker recovery times and higher success rates [6][9] Question: What are the new marketing strategies for Seresto and Advantage? - Management mentioned increased share of voice through campaigns and improved physical availability in stores, contributing to revenue growth [10][115] Question: Can you clarify the second half EBITDA bridge? - Management indicated that investments in the sales force and marketing for the U.S. Pet Health team are key components of the EBITDA bridge for the second half [80][81] Question: What is the long-term growth outlook for Seresto? - Management expressed confidence in Seresto's long-term growth, citing increased physical availability, innovation, and strong market demand [121] Question: What are the additional investments planned for next year? - Management noted that investments will focus on expanding the sales force and marketing efforts to support new product launches [103][104]

2023 Earnings – Second Quarter 2 Non-GAAP Financial Measures. This presentation contains non-GAAP financial measures, such as revenue excluding the impact of foreign exchange rate effects, EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted EPS, adjusted gross profit, adjusted gross margin, net debt and net debt leverage, which we use to assess and analyze our operational results and trends. Reconciliation of non-GAAP financial measures and reported GAAP fina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _______ COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) (State or other jurisdictio ...

Elanco Animal Health Inc. (NYSE:ELAN) Q1 2023 Results Conference Call May 9, 2023 9:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeff Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Erin Wright - Morgan Stanley Balaji Prasad - Barclays Umer Raffat - Evercore ISI Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Group Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazqu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _______ COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2500 INNOVATION WAY, GREENFIELD, INDIANA 46140 (Address an ...

Elanco Animal Health Inc. (NYSE:ELAN) Q4 2022 Results Conference Call February 21, 2023 8:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeff Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Chris Schott - JPMorgan Umer Raffat - Evercore ISI Jon Block - Stifel Elliot Wilbur - Raymond James Balaji Prasad - Barclays Brandon Vazquez - William Blair Operator Goo ...

Elanco Animal Health Incorporated (NYSE:ELAN) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeff Simmons - President & Chief Executive Officer Ellen de Brabander - Executive Vice President of Innovation & Regulatory Affairs Todd Young - Chief Financial Officer Conference Call Participants Mike Ryskin - Bank of America Erin Wright - Morgan Stanley Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Balaji Prasad - Barclays Jonat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _______ COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or ...

Elanco Animal Health Incorporated (NYSE:ELAN) Q2 2022 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeff Simmons - President & Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Chris Schott - JPMorgan Jon Block - Stifel Mike DiFiore - Evercore ISI Nathan Rich - Goldman Sachs Christine Raines - William Blair Operator Hello and thank you for ...